


PHARMACEUTICAL 2023

RVL Pharmaceuticals plc Rank 265 of 446









PHARMACEUTICAL 2023

RVL Pharmaceuticals plc Rank 265 of 446



The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 124% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 8.8% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	56,975
Cost of Goods Sold	9,456
Intangible Assets	69,747
Liabilities, Current	19,723
Liabilities, Non-Current	94
Other Assets	1,788
Other Compr. Net Income	-1,700
Other Expenses	13,290
Other Liabilities	57,600
Other Net Income	7,278
Other Revenues	49,721
Property and Equipment	0
Research and Development	3,966
Selling, General and Administrative Expense	81,979

Output Variable	Value in 1000 USD
Assets	128,510
Liabilities	77,417
Expenses	108,691
Revenues	49,721
Stockholders Equity	51,093
Net Income	-51,692
Comprehensive Net Income	-52,542
Economic Capital Ratio	34%

